Holocene Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$53.5M Buy
+217,000
New +$55.2M 0.13% 182
2025
Q4
– Sell
-13,086
Closed -$5.97M – 743
2025
Q3
$5.97M Sell
13,086
-583,730
-98% -$238M 0.01% 344
2025
Q2
$195M Buy
+596,816
New +$165M 0.47% 63
2023
Q2
– Sell
-19,547
Closed -$3.92M – 709
2023
Q1
$3.92M Sell
19,547
-579,381
-97% -$122M 0.02% 327
2022
Q4
$142M Sell
598,928
-44,721
-7% -$9.5M 0.87% 28
2022
Q3
$129M Buy
+643,649
New +$123M 0.82% 29
2022
Q2
– Sell
-799,222
Closed -$113M – 804
2022
Q1
$131M Buy
799,222
+76,483
+11% +$11.7M 0.68% 43
2021
Q4
$123M Buy
722,739
+61,509
+9% +$11.4M 0.64% 46
2021
Q3
$125M Buy
661,230
+105,991
+19% +$19.9M 0.68% 38
2021
Q2
$94.1M Buy
+555,239
New +$81.3M 0.53% 61
2019
Q4
– Sell
-117,988
Closed -$9.49M – 669
2019
Q3
$9.49M Buy
+117,988
New +$9.33M 0.1% 134

Other funds holding ALNY

Holocene Advisors's ALNY Position: Q3 2026 in Review

Holocene Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 217,000 shares worth $53.5M. The stake represents 0.13% of the portfolio and ranks #182 among its holdings. This is a return to the name: Holocene Advisors previously reported a position in ALNY as recently as Q3 2025.

Holocene Advisors first reported a position in ALNY in Q3 2019 and has held it in 11 quarters since. The position peaked at $195M in Q2 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Holocene Advisors held 217,000 shares of Alnylam Pharmaceuticals worth $53.5M as of Q3 2026.
  • Alnylam Pharmaceuticals was a new Holocene Advisors position in Q3 2026.
  • Alnylam Pharmaceuticals made up 0.13% of Holocene Advisors's portfolio in Q3 2026, its #182 holding.
  • Holocene Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
  • Holocene Advisors's Alnylam Pharmaceuticals position peaked at $195M in Q2 2025.
  • 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Holocene Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.